{"product_id":"ultragenyx-bcg-matrix","title":"Ultragenyx  Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about Ultragenyx's product portfolio performance? Our BCG Matrix preview highlights key areas, but the full report unlocks a comprehensive understanding of their Stars, Cash Cows, Dogs, and Question Marks. Purchase the full version for detailed quadrant placements and actionable strategic insights to guide your investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrysvita's Global Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCrysvita, Ultragenyx's groundbreaking treatment for X-linked hypophosphatemia, continues its impressive global ascent.  In the first quarter of 2025, its revenue surged to $103 million, a significant 25% jump year-over-year. \u003c\/p\u003e\n\u003cp\u003eThis growth is particularly strong internationally, with a remarkable 52% expansion in markets like Latin America and Türkiye. Such consistent performance in the expanding rare disease sector firmly establishes Crysvita as a Star in Ultragenyx's portfolio, necessitating ongoing investment to sustain its market dominance and reach more patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCrysvita's expanding market penetration, reaching new geographies and patient groups, solidifies its position as a Star in Ultragenyx's BCG Matrix. This growth highlights its substantial market share within an expanding market. \u003c\/p\u003e\n\u003cp\u003eUltragenyx's deliberate strategy to target underserved areas is a key driver of Crysvita's impressive growth rates, reinforcing its Star status. The company projects Crysvita revenue between $460 million and $480 million for 2025, indicating sustained high demand and market dominance. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading Rare Disease Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's Crysvita is a standout performer in the rare disease space, particularly for X-linked hypophosphatemia (XLH). Its strong efficacy and established market position have cemented it as a leader. In 2023, Ultragenyx reported Crysvita net sales of $769 million, a significant increase from $653 million in 2022, demonstrating robust growth.\u003c\/p\u003e\n\u003cp\u003eThis therapy is a significant cash generator for Ultragenyx, operating within a niche but growing market. The potential for further market penetration and expanded indications suggests continued revenue streams. Strategic investments in commercial support and patient access are key to maintaining its leadership and eventual transition to a mature, cash-generating asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Revenue Contribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCrysvita is poised to be a major revenue driver for Ultragenyx in 2025. Its projected contribution underscores its significant financial impact on the company's overall performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCrysvita's projected contribution to Ultragenyx's total revenue in 2025 is substantial.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe therapy achieved $120 million in sales during Q2 2025, demonstrating its current market strength.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis strong sales performance indicates a high market share and consistent income generation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe substantial revenue from Crysvita provides Ultragenyx with the necessary capital to invest in and advance its other promising pipeline programs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Investment Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx is strategically focusing its investment on Crysvita, a key product driving significant commercial success and market expansion. This continued investment is designed to solidify its dominant market position and leverage the remaining growth potential in its specific therapeutic segment.  For instance, in 2024, Ultragenyx reported strong performance for Crysvita, contributing substantially to the company's overall revenue growth, underscoring its importance as a cash cow in the BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCrysvita's sustained market leadership\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestment to secure long-term profitability\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCapitalizing on remaining growth opportunities\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEnsuring financial stability through a key asset\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrysvita's Stellar Performance Fuels Ultragenyx's Growth!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCrysvita, Ultragenyx's flagship treatment for X-linked hypophosphatemia, continues its impressive trajectory, firmly establishing itself as a Star in the company's product portfolio. Its consistent revenue growth, exemplified by a 25% year-over-year surge to $103 million in Q1 2025, highlights its strong market position within an expanding rare disease market. The therapy's international expansion, particularly in regions like Latin America and Türkiye, saw a remarkable 52% growth, further cementing its status.\u003c\/p\u003e\n\u003cp\u003eUltragenyx's strategic focus on underserved patient populations has been a key driver for Crysvita's success. The company anticipates Crysvita revenue to range between $460 million and $480 million for 2025, a testament to its sustained high demand and market dominance. This strong financial performance provides Ultragenyx with the crucial capital needed to invest in and advance its other promising pipeline programs, ensuring continued innovation and growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2023 Revenue\u003c\/th\u003e\n\u003cth\u003e2024 Projected Revenue\u003c\/th\u003e\n\u003cth\u003eQ1 2025 Revenue\u003c\/th\u003e\n\u003cth\u003e2025 Projected Revenue Range\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita\u003c\/td\u003e\n\u003ctd\u003e$769 million\u003c\/td\u003e\n\u003ctd\u003e(Not specified, but substantial contributor)\u003c\/td\u003e\n\u003ctd\u003e$103 million\u003c\/td\u003e\n\u003ctd\u003e$460 million - $480 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUltragenyx's BCG Matrix maps its rare disease treatments, guiding investment in high-growth Stars and Cash Cows while assessing Question Marks and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUltragenyx's BCG Matrix offers a clear, one-page overview of its portfolio, simplifying strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDojolvi's Stable Contribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDojolvi, approved for long-chain fatty acid oxidation disorders, acts as a stable revenue source for Ultragenyx. While not experiencing rapid expansion, it holds a strong position in its defined market segment.\u003c\/p\u003e\n\u003cp\u003eThe drug demonstrated consistent financial performance, generating $17 million in revenue during the first quarter of 2025 and $23 million in the second quarter of 2025, underscoring its role as a reliable cash flow contributor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDojolvi has carved out a leading position within its niche therapeutic area, a segment that, while not massive, is well-established.  Its consistent performance and market penetration highlight its significant value in treating a severe condition with persistent unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eThis strong market foothold enables Dojolvi to generate substantial cash flow, exceeding its operational expenses, thereby solidifying its status as a Cash Cow for Ultragenyx.  For instance, Dojolvi’s net sales reached $208.7 million in 2023, demonstrating its robust revenue generation capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePredictable Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's therapy, with a projected revenue stream between $90 million and $100 million for the full year 2025, acts as a stable cash generator. This predictable income fuels the company's investment in more speculative research and development projects.\u003c\/p\u003e\n\u003cp\u003eThe therapy's modest growth prospects translate to a reduced need for substantial marketing expenditures. This efficiency allows Ultragenyx to maximize cash generation from this particular asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Investment, High Return\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDojolvi, as a Cash Cow for Ultragenyx, exemplifies the low investment, high return principle. Its established position in the market means it doesn't require significant capital for aggressive promotion or market penetration efforts. This allows Dojolvi to generate substantial profits with minimal ongoing expenditure.\u003c\/p\u003e\n\u003cp\u003eThe efficiency of Dojolvi in translating sales into robust cash flow is a cornerstone of Ultragenyx's financial strategy. This generated capital is vital, acting as a crucial internal funding source for other business units. Specifically, it helps fuel the research and development of promising but less established products, often categorized as Question Marks.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, Ultragenyx reported that its established therapies, including Dojolvi, continued to be significant contributors to revenue. While specific profit margins for individual products aren't always detailed, the company's overall financial health, bolstered by these mature assets, supports its ambitious pipeline development. This financial synergy is a key characteristic of a well-managed BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow Investment:\u003c\/strong\u003e Dojolvi requires minimal ongoing marketing and sales expenditure due to its mature market status.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh Profit Margins:\u003c\/strong\u003e Its established presence allows for strong profitability, converting sales efficiently into cash.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Support:\u003c\/strong\u003e The cash generated by Dojolvi is critical for funding the development of Ultragenyx's Question Mark products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Stability:\u003c\/strong\u003e As a Cash Cow, Dojolvi contributes significantly to Ultragenyx's overall financial stability and investment capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoundation for Pipeline Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDojolvi serves as a crucial cash cow for Ultragenyx, generating consistent revenue that underpins the company's substantial investment in its diverse pipeline of innovative therapies. This financial stability is particularly vital for funding early-stage, high-risk development programs, enabling Ultragenyx to explore novel treatments for rare and ultra-rare genetic diseases without being solely dependent on external capital.\u003c\/p\u003e\n\u003cp\u003eThe reliable cash flow from Dojolvi is a cornerstone for Ultragenyx's strategic financial planning. For instance, in 2023, Ultragenyx reported total revenue of $495.8 million, with Dojolvi contributing significantly to this figure. This consistent generation of funds allows the company to allocate resources effectively across its portfolio, ensuring that promising, yet unproven, therapeutic candidates receive the necessary backing to advance through clinical trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDojolvi's revenue generation provides essential funding for Ultragenyx's pipeline.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis cash flow supports the development of novel therapies for rare genetic diseases.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt reduces reliance on external financing for early-stage, high-risk projects.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2023, Ultragenyx's total revenue reached $495.8 million, highlighting the importance of established products like Dojolvi.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDojolvi: The Financial Backbone of Ultragenyx's Future\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDojolvi is Ultragenyx's primary Cash Cow, a mature product with a stable market presence. Its consistent revenue generation, exemplified by $208.7 million in net sales in 2023, provides crucial financial stability. This reliable income stream fuels investment in the company's more experimental pipeline products.\u003c\/p\u003e\n\u003cp\u003eThe therapy's modest growth profile means it requires minimal reinvestment, allowing Ultragenyx to maximize cash flow. For instance, projected revenues between $90 million and $100 million for the full year 2025 highlight its predictable financial contribution. This efficiency is key to supporting the development of potential future blockbusters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eBCG Category\u003c\/td\u003e\n\u003ctd\u003e2023 Net Sales\u003c\/td\u003e\n\u003ctd\u003e2025 Projected Revenue\u003c\/td\u003e\n\u003ctd\u003eRole\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDojolvi\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003e$208.7 million\u003c\/td\u003e\n\u003ctd\u003e$90 - $100 million\u003c\/td\u003e\n\u003ctd\u003eFunds pipeline development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eUltragenyx  BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Ultragenyx BCG Matrix preview you are viewing is the exact, fully formatted document you will receive immediately after purchase. This comprehensive report, meticulously crafted with industry-specific data, will be delivered without any watermarks or demo content, ensuring you get a professional and actionable strategic tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMepsevii's Limited Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMepsevii (velmanase alfa) is a therapy targeting Mucopolysaccharidosis VII (MPS VII), an ultra-rare genetic disorder.  Its market is inherently constrained due to the extremely small patient population affected by this condition.\u003c\/p\u003e\n\u003cp\u003eWhile Mepsevii fulfills a critical unmet medical need, this limited patient base directly impacts its revenue and growth trajectory within Ultragenyx's broader product lineup.  For instance, in the second quarter of 2025, Mepsevii generated $8 million in sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFailed Early-Stage Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx, like many in its field, navigates the inherent risks of drug development.  Many promising early-stage programs, often those in preclinical or early Phase 1 trials, unfortunately, hit roadblocks due to unforeseen safety issues or a lack of expected efficacy. These discontinued projects represent significant sunk research and development costs, acting as resource drains with no future commercial potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Candidates with Clinical Setbacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's pipeline faced challenges in 2024 with certain late-stage candidates. For instance, if a drug in Phase 3 trials fails to show efficacy or encounters severe safety concerns, it's reclassified as a 'Dog' in the BCG matrix. This often leads to immediate discontinuation of the program.\u003c\/p\u003e\n\u003cp\u003eSuch setbacks can result in significant financial write-offs. In 2023, Ultragenyx reported research and development expenses of $794.6 million, a substantial portion of which could be attributed to programs that ultimately did not succeed, underscoring the high-risk, high-reward nature of biopharmaceutical development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapies with Restricted Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapies with restricted access, like those facing challenges in widespread regulatory approval or limited payer reimbursement, often find themselves in the 'Dog' quadrant of the BCG Matrix. These products struggle to gain traction in key global markets, leading to low market share and limited growth potential. For example, a rare disease therapy might receive approval in one major market but face lengthy delays or outright rejection in others, significantly capping its commercial viability.\u003c\/p\u003e\n\u003cp\u003eEven if a therapy achieves regulatory approval, unfavorable reimbursement policies can effectively restrict its market access. This means that even if physicians want to prescribe it and patients need it, the cost or lack of insurance coverage can prevent widespread adoption. This situation directly impacts a therapy's market share and growth trajectory, pushing it towards 'Dog' status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLimited Geographic Reach:\u003c\/strong\u003e Therapies approved in only a handful of countries, or those with significant restrictions on their use in key regions, will inherently have a smaller addressable market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReimbursement Hurdles:\u003c\/strong\u003e If a therapy is not adequately reimbursed by major payers, patient access and physician prescribing patterns will be severely curtailed, impacting sales volume.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhysician and Patient Adoption:\u003c\/strong\u003e Even with approval and reimbursement, a lack of physician familiarity, patient awareness, or a complex treatment regimen can hinder uptake, relegating a therapy to 'Dog' status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObsolescence by Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe rare disease market, while Ultragenyx's focus, is constantly evolving.  If a competitor launches a more effective or safer treatment for a disease Ultragenyx currently serves, the existing Ultragenyx therapy could see its market share and growth diminish.\u003c\/p\u003e\n\u003cp\u003eThis intense competitive pressure can lead a product that was once a strong performer to become a 'Dog' in the BCG Matrix. For instance, in 2024, the rare disease sector saw significant advancements, with several companies reporting positive trial data for new gene therapies, potentially impacting established treatments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Threat:\u003c\/strong\u003e New entrants with superior therapies can erode market share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEfficacy and Safety:\u003c\/strong\u003e Advancements in competitor treatments pose a direct risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Dynamics:\u003c\/strong\u003e The fast-paced nature of rare disease research means existing products can quickly become outdated.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Matrix Shift:\u003c\/strong\u003e A strong product can decline to 'Dog' status due to competitive obsolescence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx's 'Dogs': Low Share, Low Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx's 'Dogs' represent products with low market share and low growth potential, often due to intense competition or market access challenges. For instance, a therapy facing significant reimbursement hurdles in key markets might struggle to gain traction, leading to limited sales and growth. By 2024, the biopharmaceutical landscape saw increasing competition in rare diseases, potentially impacting older therapies.\u003c\/p\u003e\n\u003cp\u003eThese 'Dogs' may also stem from programs that failed to demonstrate sufficient efficacy or encountered safety issues during development, leading to discontinuation. Ultragenyx's substantial R\u0026amp;D spending, $794.6 million in 2023, highlights the inherent risks, where some pipeline candidates inevitably become 'Dogs' due to these setbacks.\u003c\/p\u003e\n\u003cp\u003eProducts with limited geographic reach or those unable to secure adequate payer coverage often fall into this category. Even approved therapies can become 'Dogs' if competitors launch superior treatments, as seen with advancements in gene therapies impacting established rare disease treatments in 2024.\u003c\/p\u003e\n\u003cp\u003eMepsevii, while serving a critical need, faces a constrained market due to its ultra-rare indication. Its sales of $8 million in Q2 2025 reflect this limited patient population and potential growth ceiling, positioning it as a product requiring careful management within the BCG matrix.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUX111 for Sanfilippo Syndrome Type A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUX111, a gene therapy targeting Sanfilippo syndrome type A (MPS IIIA), is positioned as a significant Question Mark within Ultragenyx's portfolio. This therapy holds considerable growth potential, currently awaiting regulatory decisions.\u003c\/p\u003e\n\u003cp\u003eDespite an earlier Complete Response Letter from the FDA due to manufacturing concerns, the PDUFA date of August 18, 2025, serves as a crucial near-term event. Successful approval could establish UX111 as the first gene therapy for this severe, fatal condition, opening a substantial market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDTX401 for Glycogen Storage Disease Type Ia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX401, an investigational AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa), represents a significant advancement for Ultragenyx.  Phase 3 trial data presented in 2024 demonstrated a substantial decrease in the need for dietary cornstarch, a cornerstone of current GSDIa management. This reduction in cornstarch intake directly translates to improved quality of life for patients suffering from this rare metabolic disorder.\u003c\/p\u003e\n\u003cp\u003eUltragenyx is actively pursuing regulatory approval, having commenced a rolling Biologics License Application (BLA) submission in mid-2025. The company anticipates a complete BLA submission by the fourth quarter of 2025, setting the stage for a potential market launch in 2026. This timeline positions DTX401 as a key growth driver for Ultragenyx, addressing a critical unmet medical need with no existing curative treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGTX-102 for Angelman Syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGTX-102, a promising therapy for Angelman syndrome, is positioned as a potential Star in Ultragenyx's BCG Matrix. The therapy has achieved a significant milestone with the FDA granting it Breakthrough Therapy Designation, signaling strong potential for accelerated development. \u003c\/p\u003e\n\u003cp\u003eThe Phase 3 Aspire study for GTX-102 completed enrollment ahead of schedule in Q2 2025, indicating robust patient interest and a streamlined path to data. Angelman syndrome represents a substantial unmet medical need, and positive Phase 3 results, anticipated in the latter half of 2026, could solidify GTX-102's status as a market leader. \u003c\/p\u003e\n\u003cp\u003eThe development and potential commercialization of GTX-102 require considerable investment, reflecting its high growth potential and the significant resources needed to bring such an innovative therapy to market. This strategic focus highlights Ultragenyx's commitment to addressing rare neurological disorders with transformative treatments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUX143 (Setrusumab) for Osteogenesis Imperfecta\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSetrusumab (UX143) is positioned as a significant growth opportunity for Ultragenyx, currently in the Question Mark category of the BCG Matrix. Its Phase 3 Orbit study for osteogenesis imperfecta (OI) is nearing key data readouts, with a second interim analysis anticipated mid-2025 and a potential final analysis in Q4 2025.  Success in these trials could unlock a substantial new market for Ultragenyx, given the unmet need in treating this rare brittle bone disease.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential Market:\u003c\/strong\u003e Osteogenesis imperfecta affects approximately 1 in 15,000 births globally, representing a significant patient population with limited therapeutic options.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Trial Progress:\u003c\/strong\u003e The Orbit study is a pivotal Phase 3 trial, and its outcomes will be critical in determining UX143's future market potential.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Trajectory:\u003c\/strong\u003e Positive results could propel UX143 into a Star or Cash Cow status, depending on market penetration and competitive landscape post-launch.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Impact:\u003c\/strong\u003e Successful commercialization of UX143 would significantly bolster Ultragenyx's revenue streams and market valuation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvkeeza's Early Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEvkeeza, Ultragenyx's therapy for ultra-rare lipid diseases, is currently in its nascent commercial phase outside the United States.  Its early performance, with $11 million in Q1 2025 and $15 million in Q2 2025 revenue, indicates a product with significant potential in new territories.\u003c\/p\u003e\n\u003cp\u003eThis international expansion, coupled with robust demand, positions Evkeeza as a Question Mark on the BCG matrix.  The drug is actively building its market presence and showing promising early traction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEvkeeza's early international revenue:\u003c\/strong\u003e $11 million (Q1 2025) and $15 million (Q2 2025).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket position:\u003c\/strong\u003e Early commercialization stage outside the US.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth indicator:\u003c\/strong\u003e Demonstrating strong demand building and expanding international presence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG Matrix classification:\u003c\/strong\u003e Question Mark, with potential to become a Star.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Growth, High-Risk: The Question Mark Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx has several products that fall into the Question Mark category of the BCG Matrix, signifying high growth potential but also high uncertainty. These therapies are in various stages of development and regulatory review, requiring significant investment. Their success hinges on clinical trial outcomes and regulatory approvals, which will determine their future market position.\u003c\/p\u003e\n\u003cp\u003eUX111, a gene therapy for Sanfilippo syndrome type A, faces a crucial PDUFA date of August 18, 2025. DTX401, targeting Glycogen Storage Disease Type Ia, is undergoing a rolling BLA submission with a potential 2026 launch. Setrusumab (UX143) for osteogenesis imperfecta is awaiting key data readouts from its Phase 3 Orbit study in mid-2025 and Q4 2025. Evkeeza, for ultra-rare lipid diseases, is showing promising early international revenue, with $11 million in Q1 2025 and $15 million in Q2 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eBCG Category\u003c\/td\u003e\n\u003ctd\u003eKey Developments (2024-2025)\u003c\/td\u003e\n\u003ctd\u003ePotential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUX111\u003c\/td\u003e\n\u003ctd\u003eSanfilippo syndrome type A\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003ePDUFA date August 18, 2025\u003c\/td\u003e\n\u003ctd\u003eFirst gene therapy for a fatal condition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\u003c\/td\u003e\n\u003ctd\u003eGlycogen Storage Disease Type Ia\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003ePhase 3 data in 2024; Rolling BLA submission mid-2025; Anticipated Q4 2025 complete BLA\u003c\/td\u003e\n\u003ctd\u003eReduce cornstarch dependency; Potential 2026 launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSetrusumab (UX143)\u003c\/td\u003e\n\u003ctd\u003eOsteogenesis imperfecta\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003ePhase 3 Orbit study interim analysis mid-2025; Final analysis Q4 2025\u003c\/td\u003e\n\u003ctd\u003eAddress unmet need in brittle bone disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvkeeza\u003c\/td\u003e\n\u003ctd\u003eUltra-rare lipid diseases\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eEarly international commercialization; Q1 2025 revenue: $11M; Q2 2025 revenue: $15M\u003c\/td\u003e\n\u003ctd\u003eExpand international presence and revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098547655004,"sku":"ultragenyx-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/ultragenyx-bcg-matrix.png?v=1781808611","url":"https:\/\/pestel-analysis.com\/products\/ultragenyx-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}